Revelation Biosciences (REVB) Competitors $2.38 -0.17 (-6.67%) Closing price 04:00 PM EasternExtended Trading$2.38 +0.00 (+0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock REVB vs. GELS, ALLR, CTXR, ATHA, TRIB, ABP, CYCC, MRKR, NEUP, and BTAIShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Gelteq (GELS), Allarity Therapeutics (ALLR), Citius Pharmaceuticals (CTXR), Athira Pharma (ATHA), Trinity Biotech (TRIB), Abpro (ABP), Cyclacel Pharmaceuticals (CYCC), Marker Therapeutics (MRKR), Neuphoria Therapeutics (NEUP), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Its Competitors Gelteq Allarity Therapeutics Citius Pharmaceuticals Athira Pharma Trinity Biotech Abpro Cyclacel Pharmaceuticals Marker Therapeutics Neuphoria Therapeutics BioXcel Therapeutics Revelation Biosciences (NASDAQ:REVB) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Is REVB or GELS more profitable? Gelteq's return on equity of 0.00% beat Revelation Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Revelation BiosciencesN/A -299.46% -115.36% Gelteq N/A N/A N/A Does the media prefer REVB or GELS? In the previous week, Revelation Biosciences had 1 more articles in the media than Gelteq. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for Gelteq. Gelteq's average media sentiment score of 0.00 beat Revelation Biosciences' score of -0.33 indicating that Gelteq is being referred to more favorably in the news media. Company Overall Sentiment Revelation Biosciences Neutral Gelteq Neutral Do insiders and institutionals have more ownership in REVB or GELS? 12.8% of Revelation Biosciences shares are held by institutional investors. 2.3% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, REVB or GELS? Gelteq has higher revenue and earnings than Revelation Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevelation BiosciencesN/AN/A-$15.04M-$307.86-0.01Gelteq$100K156.70-$2.33MN/AN/A SummaryGelteq beats Revelation Biosciences on 5 of the 8 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.64M$2.98B$5.45B$9.67BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-0.0117.8930.0425.01Price / SalesN/A174.35377.6078.24Price / CashN/A41.8335.9458.58Price / Book0.097.278.135.68Net Income-$15.04M-$54.43M$3.25B$265.58M7 Day Performance-2.46%-0.07%1.09%2.50%1 Month Performance-5.18%5.07%2.75%1.87%1 Year Performance-95.28%10.31%28.40%24.05% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences0.4132 of 5 stars$2.38-6.7%N/A-95.0%$3.64MN/A-0.0110News CoverageGap DownGELSGelteqN/A$1.67flatN/AN/A$15.77M$100K0.00N/AGap UpALLRAllarity Therapeutics2.7706 of 5 stars$1.02+0.5%$9.00+786.7%-76.5%$15.31MN/A0.0010CTXRCitius Pharmaceuticals1.917 of 5 stars$1.42+1.8%$53.00+3,645.6%-94.3%$15.10MN/A0.0020Upcoming EarningsATHAAthira Pharma3.781 of 5 stars$0.38+2.6%$11.25+2,852.8%-88.1%$14.87MN/A-0.1840News CoverageEarnings ReportGap UpTRIBTrinity Biotech1.0003 of 5 stars$0.82+0.0%N/A-67.7%$14.80M$61.56M-0.28480News CoverageUpcoming EarningsABPAbproN/A$0.24+0.9%$4.00+1,557.7%N/A$14.67M$180K0.0015Positive NewsHigh Trading VolumeCYCCCyclacel Pharmaceuticals0.5487 of 5 stars$9.08-7.4%N/A-97.5%$14.60M$14K-0.0114Upcoming EarningsMRKRMarker Therapeutics4.202 of 5 stars$1.26+1.6%$13.17+945.0%-67.5%$14.25M$6.59M-0.9560Upcoming EarningsNEUPNeuphoria Therapeutics1.1784 of 5 stars$7.55-3.0%$21.00+178.1%N/A$14.19M$10K0.00N/ABTAIBioXcel Therapeutics4.03 of 5 stars$2.38-6.4%$42.60+1,692.2%-76.6%$13.91M$2.27M-0.1790Gap Up Related Companies and Tools Related Companies Gelteq Competitors Allarity Therapeutics Competitors Citius Pharmaceuticals Competitors Athira Pharma Competitors Trinity Biotech Competitors Abpro Competitors Cyclacel Pharmaceuticals Competitors Marker Therapeutics Competitors Neuphoria Therapeutics Competitors BioXcel Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REVB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
